To the best of our knowledge, this is the first study reviewing and representing evidence for PDE-5 inhibitors efficacy in esophageal motility disorders including achalasia, hypertensive LES, and nutcracker esophagus. The gene discussed is PDE5A; the disease is Hypertension.